Bela2-microglobuline amyloidosis: Fibrillogenesis of natural and recombinant human beta2-microglobulines

Abstract


Β2-Microglobulin ( β2М) is noncovalently associated with alpha chain of the class I major histocompatibility complex. The protein is removed from blood by degradation in the proximal tubule of the kidney. β2M cannot be removed from the blood by the kidney or the dialysis membrane in patients undergoing haemodialysis. As a consequence of increased β2M concentrations, partial unfolding of β2M is believed to be prerequisite to its assembly into β2M amyloid fibrils. β2M amyloidosis is a common complication associated with long-term hemodialysis. Mechanism of fibril formation in physiological conditions is poorly understood. Simulation in vitro is required for elucidation of its mechanism and for searching after factors that can induce or inhibit fibrillogenesis. For these purpose we have devised the method to obtain β2M from dialysate of patients undergoing long-term hemodialysis. We have constructed expression plasmid for production of recombinant human β2M in E.coli with subsequent fast and easy purification. Recombinant fusion protein of β2M with green fluorescent protein was also produced. These recombinant proteins do not form inclusion bodies and can be extracted directly from the cell lysate. Electron microscopy and atomic force microscopy have shown presence of fibrils formed in vitro from the three β2M variants. Using thioflavin-T binding we have determined that β2M purified from dialysate and recombinant β2M can form amyloid fibrils.

D S Poyakov

Email: dipoi@mail.org

N A Grudinina

K V Solovyov

V V Egorov

A K Sirotkin

T D Aleinicova

Areg A Totolian

M M Shavlovsky

  1. Брок Й. Получение препаратов иммуноглобулинов // Иммунологические методы / Г. Фримель. М.: Медицина, 1987. С. 390.
  2. Ермоленко В.М. Хроническая почечная недостаточность // Нефрология: Руководство для врачей / Под ред. Іі.Е. Тареевой. М.: Медицина, 2000. С. 633- 634.
  3. Харбоу Н., Ингильд А. Иммунизация, выделение иммуноглобулинов, определение титра антител // Руководство по клиническому электрофорезу. М.: Мир, 1977. С. 200-205.
  4. Шило В., Денисов А. Позднее осложнение программного гемодиализа: бета-2-микроглобулиновый амилоидоз // Врач : Ежемесячный научно-практический и публицистический журнал. 2002. № 6. С. 7-12.
  5. Guideline 10. p2-microglobulin amyloidosis // Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease / Massry S.G., Cobum J.W. // Am. J. Kidney Dis. 2003. Vol. 42 (Suppl. 3). P. 1-202.
  6. Ausubel F.M., Brent R., Kingston R.E. et al. // Current Protocols in Molecular Biology. 1989. John Wiley & Sons, New York.
  7. Benz R.L., Siegfried J.W., Teehan B.P. Carpal tunnel syndrome in dialysis patients: Comparison between continuous ambulatory peritoneal dialysis and hemodialysis populations //Am.1. Kidney Dis. 1988. № 11. P. 473-476.
  8. Berggard I., Beam A.G. Isolation and properties of a low molecular weight B2-globulin occurring in human biological fluids // J. Biol. Chem. 1968. № 243. P. 4095-4103.
  9. Campistol J.M., Sole M., Munoz-Gomez J., Lopez-Pedret J., Revert L. Systemic involvement of dialysis-amyloidosis //Am. J. Nephrol. 1990. № ю. P. 389-396.
  10. Chiba T., Hagihara Y., Higurashi T., Hasegawa K., Nai- lci H., Goto Y. Amyloid fibril formation in the context of full-length protein. Effects of proline mutations on the amyloid fibril formation of B2-microglobulin // J. Biol. Chem. 2003. № 278. P. 47016-47024.
  11. Comelis F., Bardin T., Faller B. et al. Rheumatic syndromes and beta 2-microglobulin amyloidosis in patients receiving long-term peritoneal dialysis // Arthritis Rheum. 1989. № 32. P. 785-788.
  12. Esposito G., Michelutti R., Verdone G. et al. Removal of the N-terminal hexapeptide from human b2-micro- globulin facilitates protein aggregation and fibril formation // Protein Sci. 2000. № 9. P 831-845.
  13. Gal R., Korzets A., Schwartz A., Rath-Wolfson L., Gafter U. Systemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo longterm hemodialysis. Report of seven cases and review of the literature // Arch. Pathol. Lab. Med. 1994. № 118. P. 718-721.
  14. Goldsby R.A., Kindt T.J., Osborne B.A. Major histocompatibility complex // Kuby Immunology / Freeman W.H. 2007. P. 166-178.
  15. Jadoul M., Garbar C., Noel H., Sennesael J., Vanholder R., Bemaert P, Rorive G., Hanique G., van Ypersele, de Strihou C. Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study // Kidney Int. 1997 (Jun). Vol. 51 (6). P. 1928-1932.
  16. Kad N.M., Thomson N.H., Smith D.P., Smith D.A., Radford S.E. // J. Mol. Biol. 2001. № 313. P. 559- 571.
  17. Kayed R.K., Glabe C.G. Conformation-Dependent Anti-Amyloid Oligomer Antibodies // Methods in enzymology. 2006. Vol. 413. P. 326-344.
  18. Kihara M., Chatani E., Sakai M., Hasegawa K., Naiki H., Goto Y. Seeding-dependent maturation of (32- microglobulin amyloid fibrils at neutral pH // J. Biol. Chem. 2005. № 280. P. 12012-12018.
  19. LeVine H. Thioflavine T interaction with synthetic Alzheimer’s disease b-amyloid peptides: detection amyloid aggregation in solution // Prot. Sci. 1993. № 2. P. 404M10.
  20. Maruyama Н., Gejyo F., Aralcawa M. Clinical studies of destructive spondyloarthropathy in long-term hemodialysis patients //Nephron. 1992. № 61. P. 37- 44.
  21. McParland V.J., Kad N.M., Kalverda A.P., Brown A., Kirwin-Jones P., Hunter M. G., Sunde M., Radford S.E. // Biochemistry. 2000. № 39. P. 8735-8746.
  22. Moriniere P., Marie A., el Esper N., Fardellone P., Derarnond H., Remond A., Sebert J.L., Fournier A. Destructive spondyloarthropathy with beta 2-microglobulin amyloid deposits in a uremic patient before chronic hemodialysis //Nephron. 1991. № 59. P. 654-657.
  23. Ohashi К., Нага M., Kawai R., Ogura Y., Flonda K., Nihei H., Mimura N. Cervical discs are most susceptible to beta 2-microglobulin amyloid deposition in the vertebral column // Kidney Int. 1992. № 41. P. 1646- 1652.
  24. Pedelacq J.D., Cabantous S., Tran T., Terwilliger T.C., Waldo G.S. Engineering and characterization of a superfolder green fluorescent protein // Nat. Biotechnol. 2006. Vol. 24. № 1. P. 79-88.
  25. Sasahara K., Yagi H., Naiki FI., Goto, Y. Heat-triggered conversion of protofibrils into mature amyloid fibrils of (32-microglobulin // Biochemistry. 2007. № 46. P. 3286-3293.
  26. Sasahara K., Yagi H., Naiki H., Goto Y. Heat-induced conversion of (32-microglobulin and hen egg-white lysozyme into amyloid fibrils // J. Mol. Biol. 2007. № 372. P. 981-991.
  27. Sprague S.M., Мое S.M. Clinical manifestations and pathogenesis of dialysis-related amyloidosis // Semin. Dial. 1996. №9. P.360-369.
  28. Ventura S., Villaverde A. Protein quality in bacterial inclusion bodies // Trends Biotechnol. 2006. № 24. P. 179-185.
  29. Zingraff J.J., Noel L.H., Bardin T., Atienza C., Zins B., Drueke T.B., Kuntz D. Beta 2-microglobulin amyloidosis in chronic renal failure // N. Engl. J. Med. 1990. № 323. P. 1070-1071.

Views

Abstract - 37

Cited-By


PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2010 Poyakov D.S., Grudinina N.A., Solovyov K.V., Egorov V.V., Sirotkin A.K., Aleinicova T.D., Totolian A.A., Shavlovsky M.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies